Joachim Koch: We evolved and implemented a novel HPLC method to guide selection of antibody drug candidates.

Quoting Joachim Koch, the Vice President of Discovery Research & Translational Immunology at Affimed, on LinkedIn:

”Our latest paper is out in mAbs:

The paper describes how we evolved and implemented a novel HPLC method to guide selection of antibody drug candidates. In particular, this method allows for more physiological estimation of the serum half-life of drug candidates derived from our ROCK® platform reducing the need for cumbersome and costly mouse PK studies.”

For the article click here.
Source: Joachim Koch/LinkedIn